Search

Displaying results 4021 - 4030 of 10000 in total
  1. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    The Company determined that the program was not meeting their expected primary and exploratory objectives. … It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  2. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.

  3. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  4. Drug

    Imolamine

    go.drugbank.com/drugs/DB09284
    Investigational

    It is developed under the brand name Coremax by Novartis consumer health SA.

  5. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.

  6. Target

    Diacylglycerol kinase alpha

    go.drugbank.com/bio_entities/BE0002324
    TargetHumans

    Diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:15544348, PubMed:2175712).

    Synonyms: DAG kinase alpha
  7. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  8. Drug

    Aprotinin

    go.drugbank.com/drugs/DB06692
    ApprovedInvestigationalWithdrawn

    For this use, it is typically administered by injection. … Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death.

  9. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.

  10. Drug

    Tenamfetamine

    go.drugbank.com/drugs/DB01509
    IllicitInvestigational

    It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]